Pluripotent stem cell models of human heart disease

Cold Spring Harbor Perspectives in Medicine

Volumn 3, Issue 11, 2013, Pages

  Moretti, Alessandra ^a,b   Laugwitz, Karl Ludwig ^a,b   Dorn, Tatjana ^a   Sinnecker, Daniel ^a   Mummery, Christine ^c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE; MYOSIN LIGHT CHAIN 2; PLAKOPHILIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSCRIPTION FACTOR ETS; ZINC FINGER NUCLEASE;

ARTICLE; BRUGADA SYNDROME; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL DIFFERENTIATION; CHROMOSOME ABERRATION; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETIC HETEROGENEITY; GLYCOGEN STORAGE DISEASE TYPE 2; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART RIGHT VENTRICLE DYSPLASIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LEOPARD SYNDROME; LONG QT SYNDROME 1; LONG QT SYNDROME 2; LONG QT SYNDROME 3; MODEL; NONHUMAN; NUCLEAR REPROGRAMMING; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PROGERIA; TIMOTHY SYNDROME; TISSUE ENGINEERING; VASCULAR SMOOTH MUSCLE; WNT SIGNALING PATHWAY;

CELL DIFFERENTIATION; EPITHELIAL CELLS; FORECASTING; HEART DISEASES; HUMANS; INDIVIDUALIZED MEDICINE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; PLURIPOTENT STEM CELLS; TISSUE ENGINEERING;

EID: 84887150934     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a014027     Document Type: Article

References (86)

1. Anderson D., Self T, Mellor IR, Goh G, Hill SJ, Denning C. 2007. Transgenic enrichment of cardiomyocytes from human embryonic stem cells. Mol Therapy 15: 2027-2036.
2. Blin G., Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, Bellamy V., Rucker-Martin C, Barbry P, Bel A, et al. 2010. Apurified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 120: 1125-1139.
3. Brade T, Pane LS, Moretti A, Chien KR, Laugwitz KL. 2013. Embryonic heart progenitors and cardiogenesis. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect. a013847.
4. Bruneau B.G. 2008. The developmental genetics of congenital heart disease. Nature 451: 943-948.
5. Brunet E., Simsek D, Tomishima M, DeKelver R, Choi VM, Gregory P., Urnov F, Weinstock DM, Jasin M. 2009. Chromosomal translocations induced at specified loci in human stem cells. Proc Natl Acad Sci 106: 10620-10625.
6. Bu L., Jiang X, Martin-Puig S, Caron L, Zhu S, Shao Y, Roberts D. J, Huang PL, Domian IJ, Chien KR. 2009. Human ISL1 heart progenitors generate diverse multipotent cardiovascular cell lineages. Nature 460: 113-117.
7. Bu L., Gao X, Jiang X, Chien KR, Wang Z. 2010. Targeted conditional gene knockout in human embryonic stem cells. Cell Res 20: 379-382.
8. BurridgePW, Keller G, Gold JD, Wu JC. 2012. Production of de novo cardiomyocytes: Human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10: 16-28.
9. Cao F., Wagner RA, WilsonKD, Xie X, Fu JD, Drukker M, Lee A, Li RA, Gambhir SS, Weissman IL, et al. 2008. Transcriptional and functional profiling of human embryonic stem cell-derived cardiomyocytes. PLoS ONE 3: e3474.
10. Cao N., Liu Z, Chen Z, Wang J, Chen T, Zhao X, Ma Y, Qin L, Kang J., Wei B, et al. 2012. Ascorbic acid enhances the cardiac differentiation of induced pluripotent stem cells through promoting the proliferation of cardiac progenitor cells. Cell Res 22: 219-236.
11. Carvajal-Vergara X, Sevilla A, D'Souza SL, Ang YS, Schaniel C, Lee DF, Yang L, Kaplan AD, Adler ED, Rozov R, et al. 2010. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465: 808-812.
12. Cheung C., Bernardo AS, TrotterMW, Pedersen RA, Sinha S. 2012. Generation of human vascular smooth muscle subtypes provides insight into embryological origin-dependent disease susceptibility. Nat Biotechnol 30: 165-173.
13. Cleaver O., Melton DA. 2003. Endothelial signaling during development. Nat Med 9: 661-668.
14. Collin J., Lako M. 2011. Concise review: Putting a finger on stem cell biology: Zinc finger nuclease-driven targeted genetic editing in human pluripotent stem cells. Stem Cells 29: 1021-1033.
15. Davis R. P, Casini S, van den Berg CW, Hoekstra M, Remme CA, Dambrot C, Salvatori D, Oostwaard DW, Wilde AA, Bezzina C. R, et al. 2012. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125: 3079-3091.
16. Dubois N. C, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty A. G, Gramolini A, Keller G. 2011. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 29: 1011-1018.
17. Efe J. A, Hilcove S, Kim J, Zhou H, Ouyang K, Wang G, Chen J, Ding S. 2011. Conversion of mouse fibroblasts into cardiomyocytes using a direct reprogramming strategy. Nat Cell Biol 13: 215-222.
18. Egashira T., Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, Ohno Y, Tohyama S, Okata S, Seki T, et al. 2012. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res 95: 419-429.
19. Elliott D. A, Braam SR, Koutsis K, Ng ES, Jenny R, Lagerqvist EL, Biben C, Hatzistavrou T, Hirst CE, Yu QC, et al. 2011. NKX2-5(eGFP/w) hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat Methods 8: 1037-1040.
20. Eschenhagen T., Eder A, Vollert I, Hansen A. 2012. Physiological aspects of cardiac tissue engineering. Am J Physiol Heart Circ Physiol 303: H133-H143.
21. Fahed A. C, Gelb BD, Seidman JG, Seidman CE. 2013. Genetics of congenital heart disease: The glass half empty. Circ Res 112: 707-720.
22. Fatima A., Xu G, Shao K, Papadopoulos S, Lehmann M, Arnaiz-Cot JJ, Rosa AO, Nguemo F, Matzkies M, Dittmann S, et al. 2011. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem 28: 579-592.
23. Ge X., Ren Y, BartulosO, LeeMY, Yue Z, Kim KY, LiW, Amos PJ, Bozkulak EC, Iyer A, et al. 2012. Modeling supravalvular aortic stenosis syndrome with human induced pluripotent stem cells. Circulation 126: 1695-1704.
24. Gonzalez F., Boue S, Izpisua Belmonte JC. 2011. Methods for making induced pluripotent stem cells: Reprogramming a la carte. Nat Rev Genet 12: 231-242.
25. Gupta M. K, Illich DJ, Gaarz A, Matzkies M, Nguemo F, Pfannkuche K., Liang H, Classen S, Reppel M, Schultze JL, et al. 2010. Global transcriptional profiles of beating clusters derived from human induced pluripotent stem cells and embryonic stem cells are highly similar. BMC Dev Biol 10: 98.
26. Helgadottir A., Thorleifsson G, Magnusson KP, Gretarsdottir S, Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blankensteijn JD, Ronkainen A, et al. 2008. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysmand intracranial aneurysm. Nat Genet 40: 217-224.
27. Hewitt K. J, Garlick JA. 2013. Cellular reprogramming to reset epigenetic signatures. Mol AspectsMed 34: 841-848.
28. Hockemeyer D., Soldner F, Beard C, Gao Q, Mitalipova M, DeKelver RC, Katibah GE, Amora R, Boydston EA, Zeitler B, et al. 2009. Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat Biotechnol 27: 851-857.
29. Hockemeyer D., Wang H, Kiani S, Lai CS, Gao Q, Cassady JP, Cost G. J, Zhang L, Santiago Y, Miller JC, et al. 2011. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29: 731-734.
30. Huang H. P, Chen PH, Hwu WL, Chuang CY, Chien YH, Stone L., Chien CL, Li LT, Chiang SC, Chen HF, et al. 2011. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. Hum Mol Genet 20: 4851-4864.
31. Huber I., Itzhaki I, Caspi O, Arbel G, Tzukerman M, Gepstein A, Habib M, Yankelson L, Kehat I, Gepstein L. 2007. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 21: 2551-2563.
32. Ieda M., Fu JD, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau B. G, Srivastava D. 2010. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142: 375-386.
33. Irion S., Luche H, Gadue P, Fehling HJ, Kennedy M, Keller G. 2007. Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol 25: 1477-1482.
34. Islas J. F, Liu Y, Weng KC, Robertson MJ, Zhang S, Prejusa A, Harger J., Tikhomirova D, Chopra M, Iyer D, et al. 2012. Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors. Proc Natl Acad Sci 109: 13016-13021.
35. Itzhaki I., Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, et al. 2011a. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471: 225-229.
36. Itzhaki I., Rapoport S, Huber I, Mizrahi I, Zwi-Dantsis L, Arbel G., Schiller J, Gepstein L. 2011b. Calcium handling in human induced pluripotent stem cell derived cardiomyocytes. PLoS ONE 6: e18037.
37. Itzhaki I., Maizels L, Huber I, Gepstein A, Arbel G, Caspi O, Miller L., Belhassen B, Nof E, Glikson M, et al. 2012. Modeling of catecholaminergic polymorphic ventricular tachycardiawith patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol 60: 990-1000.
38. Jacoby D., McKenna WJ. 2012. Genetics of inherited cardiomyopathy. Eur Heart J 33: 296-304.
39. Jiang X., Rowitch DH, Soriano P, McMahon AP, Sucov HM. 2000. Fate of the mammalian cardiac neural crest. Development 127: 1607-1616.
40. Jung C. B, Moretti A, Mederos y Schnitzler M, Iop L, Storch U, Bellin M, Dorn T, Ruppenthal S, Pfeiffer S, Goedel A, et al. 2012. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med 4: 180-191.
41. Kathiresan S., Srivastava D. 2012. Genetics of human cardiovascular disease. Cell 148: 1242-1257.
42. Kattman S. J, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, Keller G. 2011. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8: 228-240.
43. Kim K., Doi A, Wen B, Ng K, Zhao R, Cahan P, Kim J, Aryee MJ, Ji H, Ehrlich LI, et al. 2010. Epigenetic memory in induced pluripotent stem cells. Nature 467: 285-290.
44. Kim C., Wong J, Wen J, Wang S, Wang C, Spiering S, Kan NG, Forcales S., Puri PL, Leone TC, et al. 2013. Studying arrhythmogenic right ventricular dysplasia with patientspecific iPSCs. Nature 494: 105-110.
45. Laflamme M. A, Chen KY, Naumova AV, Muskheli V, Fugate JA, Dupras SK, Reinecke H, Xu C, Hassanipour M, Police S, et al. 2007. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25: 1015-1024.
46. Lahti A. L, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M., Kerkela E, Hyttinen J, Kontula K, Swan H, Conklin B. R, et al. 2012. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5: 220-230.
47. Lan F., Lee AS, Liang P, Sanchez-Freire V, Nguyen PK, Wang L, Han L, Yen M, Wang Y, Sun N, et al. 2013. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12: 101-113.
48. Lee H. J, Kim E, Kim JS. 2010. Targeted chromosomal deletions in human cells using zinc finger nucleases. Genome Res 20: 81-89.
49. Lieu D. K, Liu J, SiuCW, McNerneyGP, TseHF, Abu-Khalil A, Huser T., Li RA. 2009. Absence of transverse tubules contributes to non-uniform Ca2+ wavefronts in mouse and human embryonic stem cell-derived cardiomyocytes. Stem Cells Dev 18: 1493-1500.
50. Lundy S. D, Zhu WZ, Regnier M, Laflamme M. 2013. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev 22: 1991-2002.
51. Ma D., Wei H, Lu J, Ho S, Zhang G, Sun X, Oh Y, Tan SH, Ng ML, Shim W, et al. 2013. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 34: 1122-1133.
52. Majesky M.W. 2007. Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 27: 1248-1258.
53. Martin C. A, Matthews GD, Huang CL. 2012. Sudden cardiac death and inherited channelopathy: The basic electrophysiology of the myocyte and myocardium in ion channel disease. Heart 98: 536-543.
54. Matsa E., Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C. 2011. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QTsyndrome type 2 mutation. Eur Heart J 32: 952-962.
55. Mikawa T., Gourdie RG. 1996. Pericardial mesoderm generates a population of coronary smooth muscle cells migrating into the heart along with ingrowth of the epicardial organ. Dev Biol 174: 221-232.
56. Moretti A., Bellin M, Jung CB, Thies TM, Takashima Y, Bernshausen A., Schiemann M, Fischer S, Moosmang S, Smith A. G, et al. 2010a. Mouse and human induced pluripotent stem cells as a source for multipotent Isl1+ cardiovascular progenitors. FASEB J 24: 700-711.
57. Moretti A., Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, et al. 2010b. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 363: 1397-1409.
58. Mummery C., Ward-van Oostwaard D, Doevendans P, Spijker R., van den Brink S, Hassink R, van der Heyden M, Opthof T, Pera M, de la Riviere AB, et al. 2003. Differentiation of human embryonic stem cells to cardiomyocytes: Role of coculture with visceral endodermlike cells. Circulation 107: 2733-2740.
59. Nam Y. J, Song K, Luo X, Daniel E, Lambeth K, West K, Hill JA, DiMaio JM, Baker LA, Bassel-Duby R, et al. 2013. Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci 110: 5588-5593.
60. Novak A., Barad L, Zeevi-Levin N, Shick R, Shtrichman R, Lorber A., Itskovitz-Eldor J, Binah O. 2012. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation. J Cell Mol Med 16: 468-482.
61. Ohi Y., Qin H, Hong C, Blouin L, Polo JM, Guo T, Qi Z, Downey S. L, Manos PD, Rossi DJ, et al. 2011. Incomplete DNA methylation underlies a transcriptional memory of somatic cells in human iPS cells. Nat Cell Biol 13: 541-549.
62. Onder T. T, Daley GQ. 2012. New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev 22: 500-508.
63. Paige S. L, Osugi T, Afanasiev OK, Pabon L, Reinecke H, Murry C.E. 2010. Endogenous Wnt/b-catenin signaling is required for cardiac differentiation in human embryonic stem cells. PLoS ONE 5: e11134.
64. Papp B., Plath K. 2013. Epigenetics of reprogramming to induced pluripotency. Cell 152: 1324-1343.
65. Park I. H, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochedlinger K, Daley GQ. 2008. Disease-specific induced pluripotent stem cells. Cell 134: 877-886.
66. Robinton D. A, Daley GQ. 2012. The promise of induced pluripotent stem cells in research and therapy. Nature 481: 295-305.
67. Satin J., Itzhaki I, Rapoport S, Schroder EA, Izu L, Arbel G, Beyar R., Balke CW, Schiller J, Gepstein L. 2008. Calcium handling in human embryonic stem cell-derived cardiomyocytes. Stem Cells 26: 1961-1972.
68. Schaaf S., Shibamiya A, MeweM, Eder A, Stohr A, Hirt MN, Rau T., Zimmermann WH, Conradi L, Eschenhagen T, et al. 2011. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS ONE 6: e26397.
69. Sun N., Yazawa M, Liu J, Han L, Sanchez-Freire V, Abilez OJ, Navarrete E. G, Hu S, Wang L, Lee A, et al. 2012. Patientspecific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 4: 130ra147.
70. Takahashi K., Yamanaka S. 2006. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663-676.
71. Takahashi K., Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K., Yamanaka S. 2007. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
72. Tanasijevic B., Dai B, Ezashi T, Livingston K, Roberts RM, Rasmussen T.P. 2009. Progressive accumulation of epigenetic heterogeneity during human ES cell culture. Epigenetics 4: 330-338.
73. Thomson J. A, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel J. J, Marshall VS, Jones JM. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282: 1145-1147.
74. Uosaki H., FukushimaH, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S, Yamashita JK. 2011. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS ONE 6: e23657.
75. Urbach A., Schuldiner M, Benvenisty N. 2004. Modeling for Lesch-Nyhan disease by gene targeting in human embryonic stem cells. Stem Cells 22: 635-641.
76. Van Hoof D, Dormeyer W, Braam SR, Passier R, Monshouwer-Kloots J., Ward-van Oostwaard D, Heck AJ, Krijgsveld J., Mummery CL. 2010. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J Proteome Res 9: 1610-1618.
77. Waldo K. L, Hutson MR, Ward CC, Zdanowicz M, Stadt HA, KumiskiD, Abu-Issa R, Kirby ML. 2005. Secondary heart field contributes myocardium and smooth muscle to the arterial pole of the developing heart. Dev Biol 281: 78-90.
78. Wasteson P., Johansson BR, Jukkola T, Breuer S, Akyurek LM, Partanen J., Lindahl P. 2008. Developmental origin of smooth muscle cells in the descending aorta in mice. Development 135: 1823-1832.
79. Wood A. J, Lo TW, Zeitler B, Pickle CS, Ralston EJ, Lee AH, Amora R., Miller JC, Leung E, Meng X, et al. 2011. Targeted genome editing across species using ZFNs and TALENs. Science 333: 307.
80. Yang L., Soonpaa MH, Adler ED, Roepke TK, Kattman SJ, Kennedy M., Henckaerts E, Bonham K, Abbott GW, Linden RM, et al. 2008. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 453: 524-528.
81. Yazawa M., Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE. 2011. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471: 230-234.
82. Yu J., Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, et al. 2007. Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.
83. Zhang J., Lian Q, Zhu G, Zhou F, Sui L, Tan C, Mutalif RA, Navasankari R., Zhang Y, Tse HF, et al. 2011a. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8: 31-45.
84. Zhang Q., Jiang J, Han P, Yuan Q, Zhang J, Zhang X, Xu Y, Cao H., Meng Q, Chen L, et al. 2011b. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res 21: 579-587.
85. Zhu W. Z, Xie Y, Moyes KW, Gold JD, Askari B, Laflamme MA. 2010. Neuregulin/ErbB signaling regulates cardiac subtype specification in differentiating human embryonic stem cells. Circ Res 107: 776-786.
86. Zou J., Maeder ML, Mali P, Pruett-Miller SM, Thibodeau-Beganny S., Chou BK, Chen G, Ye Z, Park IH, Daley GQ, et al. 2009. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5: 97-110.